JP2011526918A5 - - Google Patents

Download PDF

Info

Publication number
JP2011526918A5
JP2011526918A5 JP2011516833A JP2011516833A JP2011526918A5 JP 2011526918 A5 JP2011526918 A5 JP 2011526918A5 JP 2011516833 A JP2011516833 A JP 2011516833A JP 2011516833 A JP2011516833 A JP 2011516833A JP 2011526918 A5 JP2011526918 A5 JP 2011526918A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
release formulation
sustained release
oral sustained
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011516833A
Other languages
English (en)
Japanese (ja)
Other versions
JP6092514B2 (ja
JP2011526918A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/049322 external-priority patent/WO2010002937A1/en
Publication of JP2011526918A publication Critical patent/JP2011526918A/ja
Publication of JP2011526918A5 publication Critical patent/JP2011526918A5/ja
Application granted granted Critical
Publication of JP6092514B2 publication Critical patent/JP6092514B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011516833A 2008-06-30 2009-06-30 ５−フルオロシトシン製剤およびその使用 Expired - Fee Related JP6092514B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7714208P 2008-06-30 2008-06-30
US61/077,142 2008-06-30
PCT/US2009/049322 WO2010002937A1 (en) 2008-06-30 2009-06-30 Formulations of 5-fluorocytosine and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014227208A Division JP6170896B2 (ja) 2008-06-30 2014-11-07 ５−フルオロシトシン製剤およびその使用

Publications (3)

Publication Number Publication Date
JP2011526918A JP2011526918A (ja) 2011-10-20
JP2011526918A5 true JP2011526918A5 (enExample) 2012-07-19
JP6092514B2 JP6092514B2 (ja) 2017-03-08

Family

ID=41466310

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011516833A Expired - Fee Related JP6092514B2 (ja) 2008-06-30 2009-06-30 ５−フルオロシトシン製剤およびその使用
JP2014227208A Expired - Fee Related JP6170896B2 (ja) 2008-06-30 2014-11-07 ５−フルオロシトシン製剤およびその使用
JP2017130096A Pending JP2017214398A (ja) 2008-06-30 2017-07-03 ５−フルオロシトシン製剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014227208A Expired - Fee Related JP6170896B2 (ja) 2008-06-30 2014-11-07 ５−フルオロシトシン製剤およびその使用
JP2017130096A Pending JP2017214398A (ja) 2008-06-30 2017-07-03 ５−フルオロシトシン製剤およびその使用

Country Status (11)

Country Link
US (4) US9320738B2 (enExample)
EP (1) EP2306823A4 (enExample)
JP (3) JP6092514B2 (enExample)
KR (2) KR101950635B1 (enExample)
CN (2) CN102076215A (enExample)
AU (1) AU2009267052B2 (enExample)
BR (1) BRPI0915284B1 (enExample)
CA (1) CA2724740C (enExample)
IL (3) IL209385A (enExample)
MX (2) MX337213B (enExample)
WO (1) WO2010002937A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115290B1 (en) 1998-10-01 2009-03-04 University of Southern California Retroviral gene delivery system and methods of use
WO2010002937A1 (en) 2008-06-30 2010-01-07 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
KR102025502B1 (ko) 2008-09-26 2019-09-25 토카겐 인크. 유전자 요법 벡터와 시토신 디아미나아제
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
EP2443242B1 (en) 2009-06-17 2016-10-26 Tocagen Inc. Producer cells for replication competent retroviral vectors
WO2011057176A1 (en) * 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
CA2816570A1 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
CN102579450B (zh) * 2012-02-10 2013-07-24 上海市嘉定区南翔医院 5-氟尿嘧啶在制备局限性慢性湿疹治疗药物上的应用
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
EP3325633A4 (en) 2015-09-04 2019-01-16 Tocagen Inc. RECOMBINANT VECTORS COMPRISING A 2A PEPTIDE
EP3595675A4 (en) * 2017-03-14 2020-12-30 Memorial Sloan Kettering Cancer Center MARKING, ISOLATION AND ANALYSIS OF RNA FROM RARE CELLULAR POPULATIONS
US20190380965A1 (en) * 2018-06-15 2019-12-19 Hemant N. Joshi Quick Water-Dispersible Pharmaceutical Compositions of Flucytosine
WO2020172671A1 (en) * 2019-02-22 2020-08-27 Advantagene, Inc. Gmci and ddri combination therapy for treating cancer
WO2021186399A1 (en) 2020-03-18 2021-09-23 Marvell Israel (M.I.S.L) Ltd. Packet buffer spill-over in network devices
CN111937887B (zh) * 2020-07-15 2021-09-07 南京师范大学 5-氟-2’-脱氧尿苷在抑制和/或防治螺旋藻规模化生产中褶皱臂尾轮虫的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279542B6 (sk) 1991-03-06 1998-12-02 The Wellcome Foundation Limited U
FI980901A7 (fi) 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
EP1115290B1 (en) 1998-10-01 2009-03-04 University of Southern California Retroviral gene delivery system and methods of use
JP4928668B2 (ja) * 1999-03-31 2012-05-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 制御放出製剤中の前糊化澱粉
US6677155B1 (en) * 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
AU6085500A (en) 1999-07-08 2001-01-30 Regents Of The University Of California, The A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
JP4021627B2 (ja) * 2000-03-22 2007-12-12 株式会社東芝 遺伝子検出用担体、及びインターフェロン療法の有効性を検出するためのその使用
IL153497A0 (en) 2000-06-23 2003-07-06 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CN1244321C (zh) * 2003-06-26 2006-03-08 李勇 用于胃癌治疗的5－氟尿嘧啶胃内漂浮滞留双层缓释片
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
FR2874325B1 (fr) 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US7968698B2 (en) 2005-05-25 2011-06-28 The Regents Of The University Of California Optimized core promoters and uses thereof
JPWO2007069358A1 (ja) 2005-12-14 2009-05-21 キッセイ薬品工業株式会社 新規胃内滞留製剤
CN101085355B (zh) * 2007-06-20 2012-01-25 山东大学 5-氟胞嘧啶/类水滑石纳米杂化物及其制备方法
US20090068287A1 (en) 2007-09-12 2009-03-12 Susan Welsh Novel topical formulations of flucytosine and uses thereof
US9314524B2 (en) 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
WO2010002937A1 (en) * 2008-06-30 2010-01-07 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
KR102025502B1 (ko) 2008-09-26 2019-09-25 토카겐 인크. 유전자 요법 벡터와 시토신 디아미나아제
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CA2805803A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (hppd) activity

Similar Documents

Publication Publication Date Title
JP2011526918A5 (enExample)
ES2661723T3 (es) Forma galénica oral microparticulada para la liberación retardada y controlada de principios activos farmacéuticos
ES2284507T3 (es) Procedimiento de fabricacion de granulos revestidos con sabor enmascarado y de liberacion inmediata del principio activo.
JP6170896B2 (ja) ５−フルオロシトシン製剤およびその使用
JP2013501718A5 (enExample)
TWI302460B (en) Pharmaceutical compositions and use thereof
JP2016006108A5 (enExample)
JP2012153724A5 (enExample)
JP2007119479A5 (enExample)
JP2010502762A5 (enExample)
CN101466392B (zh) 用于预防或治疗hiv感染的药用组合物及其应用
TWI835118B (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途
RU2010109408A (ru) Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия
RU2015107517A (ru) Фармацевтические композиции мемантина
FI4138789T3 (fi) Uusi viivästetysti vapauttava koostumus annettavaksi suun kautta
WO2005055955B1 (en) DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
JP2004507487A (ja) 腸疾患治療薬
CN102357078A (zh) 一种缬沙坦固体分散体及其制备方法
TW200911303A (en) Powders for reconstitution
JP5064226B2 (ja) 不眠症の治療において有用な新規な製剤処方
JP2010506855A5 (enExample)
EP4232460A1 (en) Compositions of anti-viral peptides and/or compounds and methods of use thereof
WO2024220974A1 (en) Rimegepant fast-dissolving films for oral administration
TR201801650T1 (tr) Kontrollü salim propi̇veri̇n formülasyonlari
JP2012031164A (ja) フィルム状製剤